RxDoctor Payments Data

Arnold Greenberg, MD

Neurology · San Francisco, CANPI 1780616177

Payments from drug & device makers

$18,122in general payments, 2019–2025

Across 747 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • UCB, Inc.$2K
  • AbbVie$2K
  • SK Life Science, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • Eisai Inc.$811
  • plus $10K from 44 others

What the payments were for

  • Speaking & faculty fees$200%
  • Food & beverage$17,88999%
  • Education$2131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,122 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$124,835
Medicare patients
531
Services billed
994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe133$132,023
Emgality PenGalcanezumab-Gnlm113$124,508
Nurtec OdtRimegepant Sulfate53$77,406
GraliseGabapentin52$60,873
Ajovy SyringeFremanezumab-Vfrm36$34,799
Ajovy AutoinjectorFremanezumab-Vfrm19$28,662
NuedextaDextromethorphan Hbr/Quinidine18$28,346
ExelonRivastigmine30$22,722
HorizantGabapentin Enacarbil19$21,773
BelsomraSuvorexant34$14,828
UbrelvyUbrogepant14$12,544
Memantine Hcl ErMemantine Hcl65$11,278
ZtlidoLidocaine23$8,123
Lidocaine55$5,659
Gabapentin488$5,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$601$77,40653 claims
Almatica Pharma LLCGralise, Sertraline Hcl$206$61,02889 claims
Avanir Pharmaceuticals, Inc.Nuedexta$627$28,34618 claims
NovartisExelon$177$22,72230 claims
Arbor Pharmaceuticals, Inc.Horizant$245$21,77319 claims
MerckBelsomra$141$14,82834 claims
AbbVieUbrelvy$1,519$12,54414 claims
Scilex Pharmaceuticals Inc.Ztlido$183$8,12323 claims
Upsher-smith Laboratories LLCTopiramate$96$979120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →